Abstract
As of July, 2021, almost 3 billion doses of COVID-19 vaccines have been administered globally.1 However, there remains an urgent need to broaden access to safe and effective COVID-19 vaccines, especially in low-income and middle-income countries experiencing surges in SARS-CoV-2 infections. Inactivated viral vaccines are an established technology and have several advantages for large-scale roll-out, including their stability at normal refrigeration temperatures and their long shelf-life.2 Several inactivated SARS-CoV-2 candidate vaccines are in phase 3/4 trials, and two have received WHO emergency use authorisation: CoronaVac (developed by Sinovac Life Sciences, Beijing, China) and BBIBP-CorV (Sinopharm, Beijing, China).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
